General
Preferred name
EMPAGLIFLOZIN
Synonyms
BI 10773 ()
Jardiance ()
Empagliflozin (BI 10773) ()
Empagliflozin-d4 ()
Empagliflozine ()
Empagliflozina ()
Empagliflozin component of synjardy ()
Empagliflozin component of trijardy xr ()
Bi10773 ()
BI-10773 ()
Empagliflozin component of glyxambi ()
BI10773 ()
EMPAGLIFLOZIN COMPONENT OF GLYXAMBI ()
EMPAGLIFLOZIN COMPONENT OF SYNJARDY ()
EMPAGLIFLOZIN COMPONENT OF TRIJARDY XR ()
EMPAGLIFLOZINA ()
EMPAGLIFLOZINE ()
P&D ID
PD009397
CAS
864070-44-0
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
2014
Drug indication
Type-1 diabetes
diabetes mellitus
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Empagliflozin is a member of the 'gliflozin' class of drugs which inhibit reabsorption of glucose in the kidney to lower blood sugar.
It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease.
SARS-CoV-2 and COVID-19: Empagliflozin was added to the RECOVERY trial (NCT04381936) in July 2021, to determine if using empagliflozin to correct metabolic dysregulation caused by SARS-CoV-2 infection can protect against organ damage and improve recovery in COVID-19 patients. This was predicated by results of a study exploring -mediated organ protection, which found that the drug elicited a non-significant reduction in the risk of organ failure or death in COVID-19 patients . (GtoPdb)
It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease.
SARS-CoV-2 and COVID-19: Empagliflozin was added to the RECOVERY trial (NCT04381936) in July 2021, to determine if using empagliflozin to correct metabolic dysregulation caused by SARS-CoV-2 infection can protect against organ damage and improve recovery in COVID-19 patients. This was predicated by results of a study exploring -mediated organ protection, which found that the drug elicited a non-significant reduction in the risk of organ failure or death in COVID-19 patients . (GtoPdb)
DESCRIPTION
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].
PRICE
51
DESCRIPTION
Empagliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus.
(Enamine Bioactive Compounds)
DESCRIPTION
Empagliflozin (BI 10773) is an SGLT-2 inhibitor (IC50=3.1 nM) that is potent and selective, with more than 300-fold selectivity for SGLT-1/4/5/6. Empagliflozin is used for the treatment of type 2 diabetes.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
23
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
56
Molecular Weight
450.14
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
4
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
2
cLogP
1.61
TPSA
108.61
Fraction CSP3
0.48
Chiral centers
6.0
Largest ring
6.0
QED
0.53
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
SGLT
SGLT1
SGLT2
SGLT4
SGLT5
SGLT6
SLC5A1, SLC5A2
SGLT2 inhibitor
Indication
diabetes mellitus
MOA
sodium/glucose cotransporter inhibitor
Biosynthetic Origin
Carbohydrate
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Pathway
Membrane Transporter/Ion Channel
GPCR/G protein
Recommended Cell Concentration
None
Source data
